Generali Asset Management SPA SGR bought a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,197 shares of the medical research company's stock, valued at approximately $2,004,000.
A number of other institutional investors have also added to or reduced their stakes in the company. Synergy Asset Management LLC acquired a new position in shares of IQVIA during the 4th quarter worth about $33,000. Avior Wealth Management LLC increased its holdings in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock worth $38,000 after acquiring an additional 87 shares during the last quarter. Meeder Asset Management Inc. raised its stake in IQVIA by 353.7% in the 3rd quarter. Meeder Asset Management Inc. now owns 245 shares of the medical research company's stock valued at $58,000 after acquiring an additional 191 shares during the period. Versant Capital Management Inc boosted its position in IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after purchasing an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new position in shares of IQVIA in the fourth quarter valued at $60,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.
IQVIA Price Performance
Shares of IQVIA stock traded up $0.46 during midday trading on Monday, hitting $186.35. 1,477,630 shares of the company traded hands, compared to its average volume of 1,240,830. The stock has a market cap of $32.86 billion, a price-to-earnings ratio of 24.85, a PEG ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm's fifty day moving average price is $194.94 and its 200-day moving average price is $208.16. IQVIA Holdings Inc. has a 12 month low of $179.28 and a 12 month high of $254.54.
IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.
Analyst Ratings Changes
A number of research firms have recently issued reports on IQV. Barclays cut their target price on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a research note on Monday, February 3rd. Bank of America reduced their price objective on IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a report on Friday, December 13th. Robert W. Baird lowered their target price on IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 21st. Royal Bank of Canada restated an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. Finally, Citigroup lowered their price objective on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $249.05.
View Our Latest Research Report on IQV
IQVIA Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
